Dodge & Cox Lowers Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Dodge & Cox cut its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 2.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,540,262 shares of the biopharmaceutical company's stock after selling 82,273 shares during the quarter. Dodge & Cox owned about 2.74% of Alnylam Pharmaceuticals worth $833,059,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Jump Financial LLC bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $3,564,000. Bridgewater Associates LP grew its position in Alnylam Pharmaceuticals by 222.3% in the 4th quarter. Bridgewater Associates LP now owns 6,452 shares of the biopharmaceutical company's stock valued at $1,518,000 after acquiring an additional 4,450 shares during the last quarter. Ontario Teachers Pension Plan Board purchased a new stake in Alnylam Pharmaceuticals in the fourth quarter worth $364,000. Aware Super Pty Ltd as trustee of Aware Super bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $3,216,000. Finally, Mariner LLC boosted its stake in shares of Alnylam Pharmaceuticals by 16.6% during the fourth quarter. Mariner LLC now owns 13,666 shares of the biopharmaceutical company's stock valued at $3,216,000 after purchasing an additional 1,947 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Performance

ALNY stock traded up $4.06 during trading on Friday, reaching $234.56. The company had a trading volume of 601,349 shares, compared to its average volume of 872,674. The company has a market cap of $30.51 billion, a price-to-earnings ratio of -108.09 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The firm has a 50-day simple moving average of $249.14 and a 200-day simple moving average of $256.97.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Redburn Atlantic initiated coverage on shares of Alnylam Pharmaceuticals in a report on Monday, March 31st. They set a "buy" rating and a $353.00 price objective for the company. William Blair reaffirmed an "outperform" rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Canaccord Genuity Group increased their price objective on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a research note on Friday, March 21st. Stifel Nicolaus raised their price objective on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a "buy" rating in a report on Monday, March 31st. Finally, StockNews.com cut Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have given a buy rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $315.58.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 1,213 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $309,521.21. Following the sale, the chief executive officer now owns 81,526 shares in the company, valued at $20,802,989.42. This represents a 1.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Jeffrey V. Poulton sold 967 shares of the business's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $246,749.39. Following the transaction, the chief financial officer now owns 32,786 shares of the company's stock, valued at $8,366,003.62. This represents a 2.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 71,234 shares of company stock worth $19,958,097 over the last three months. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.